During Tuesday’s Afternoon trade, Shares of Endologix, Inc. (NASDAQ:ELGX), gain 0.69% to $13.14.
Endologix, Inc. (ELGX), declared financial results for the three and six months ended June 30, 2015.
Financial Results
Global revenue in the second quarter of 2015 was $39.5 million, a 3% enhance from $38.3 million in the second quarter of 2014. For the six months ended June 30, 2015, global revenue raised 6% to $76.1 million, contrast to $71.6 million for the six months ended June 30, 2014. On a constant currency basis, revenue for the second quarter and six months ended June 30, 2015 raised 8% and 11%, respectively.
U.S. revenue in the second quarter of 2015 was $28.8 million, a 14% sequential enhance from the first quarter of 2015 and a 3% enhance contrast with $28.0 million in the second quarter of 2014. International revenue was $10.7 million, a 4% enhance contrast to $10.3 million in the second quarter of 2014. On a constant currency basis, second quarter international revenue raised 20%. European revenue was $7.9 million, a 1% enhance as contrast to $7.8 million in the second quarter of 2014, but 23% growth on a constant currency basis.
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular repair (EVAR) products, counting EVAR stent graft and catheter delivery system under the brand names Powerlink, IntuiTrak, AFX, and VELA Proximal Endograft.
Shares of Hollysys Automation Technologies Ltd (NASDAQ:HOLI), declined -3.26% to $18.10, during its Afternoon trading session.
Hollysys Automation Technologies, Ltd. (NASDAQ:HOLI) a leading provider of automation and control technologies and applications in China, recently declared its unaudited financial results for the fiscal year 2015 and the quarter ended on June 30, 2015 (see attached tables). The administration of Hollysys, stated:
Fiscal Year 2015 Financial Highlights
- Non-GAAP net income attributable to Hollysyswas $103.3 million, an enhance of 18.9% contrast to the preceding year.
- Total revenueswere $531.4 million, an enhance of 1.9% contrast to the preceding year.
- Non-GAAP gross marginwas at 41.2%, contrast to 34.7% from the preceding year.
- Non-GAAP diluted EPSwere at $1.72, an enhance of 15.4% contrast to the preceding year.
- Integrated Contracts Backlogwas $568.5 million, an enhance of 2.3% contrast to the comparable preceding year period.
- Net cash offered by operating activitiesof $79.5 million for fiscal year 2015.
- DSOof 176 days, contrast to 150 days from the preceding year.
- Inventory turnover daysof 41 days, contrast to 36 days from the preceding year.
Hollysys Automation Technologies Ltd. provides automation and control technologies and products to customers in industrial, railway, subway, nuclear power, building retrofit, and mechanical and electronic industries primarily in the People’s Republic China, Hong Kong, Southeast Asia, and the Middle East. The company offers industrial automation solutions, counting third-party hardware-centric products; proprietary software-centric distributed control systems/programmable logic controllers; and valued-added software packages, such as real-time administration information system, HolliAS asset administration system, operator training system, HolliAS BATCH application package, HolliAS advanced process control package, and safety instrumentation system.
Vantage Drilling Company (NYSEMKT:VTG), during its Tuesday’s Afternoon trading session gained 3.87% to $0.161.
Vantage Drilling Company (VTG) reports net income for the three months ended June 30, 2015 of $25.0 million or $.07 per diluted share as contrast to earnings of $10.2 million or $.03 per diluted share for the three months ended June 30, 2014.
The three months ended June 30, 2015 comprises about $5.6 million of gains on the early retirement of debt as contrast to a loss on the early retirement of debt of $1.4 million in the preceding year. The strong operating results for the second quarter also required us to re-evaluate our effective tax rate for the year and combined with tax impact of the early retirement of debt resulted in a $2.7 million favorable adjustment to our tax provision as contrast to a $3.5 million unfavorable adjustment in the second quarter 2014. Adjusting for these items, pro forma net income for the three months ended June 30, 2015 was about $16.6 million or $.05 per diluted share as contrast to $15.1 million or $.05 per diluted share for the three months ended June 30, 2014.
Vantage Drilling Company, through its auxiliaries, provides offshore contract drilling services in the United States and internationally. It offers drilling units, related equipment, and work crews under contract to drill oil and natural gas wells. The company also provides construction supervision and operations administration services for drilling units owned by others. As of March 6, 2015, it owned a fleet of seven drilling units, counting three ultra-deepwater drillships and four ultra-premium jackup rigs.
Finally, Cempra Inc (NASDAQ:CEMP), decreased -1.67%, to $36.99.
Cempra, Inc. (CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, recently declared the completion of enrollment for the global Solitaire-IV Phase 3 trial of solithromycin in adult patients with moderate to moderately severe community-attained bacterial pneumonia (CABP). Top-line efficacy and safety data from this study are predictable to be declared by the end of the year.
Cempra, Inc., a clinical-stage pharmaceutical company, focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America. Its lead product candidates comprise solithromycin (CEM-101), which is in Phase III clinical trials for the treatment of community attained bacterial pneumonia, in addition to for uncomplicated bacterial urethritis; and Taksta (CEM-102), an antibiotic that has accomplished Phase II clinical trials for refractory bone and joint infections.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
